Literature DB >> 6794038

Potentiation by deprenil of 1-dopa induced circling in nigral-lesioned rats.

R E Heikkila, F S Cabbat, L Manzino, R C Duvoisin.   

Abstract

1-Deprenil, a potent inhibitor of type B monoamine oxidase, was a weak inhibitor of 3H-dopamine uptake as well as a weak releasing agent for previously accumulated 3H-dopamine in rat neostriatal tissue slices. In similar experiments d-amphetamine as approximately 100 times as potent as 1-deprenil as a releasing agent. When deprenil (20 mg/kg IP) was given to rats with a unilateral 6-hydroxydopamine lesion of the substantia nigra, it brought about a moderate but long-lasting ipsilateral rotational behavior. 1-Dopa (20-40 mg/kg, IP) by itself caused a considerably stronger rotation in the opposite direction (contralateral). When 1-dopa was given to rats 1 hr after 1-deprenil, there was a considerably greater contralateral rotation than after 1-dopa alone. Clorgyline, a type A monoamine oxidase inhibitor, which by itself at 20 mg/kg caused no rotation, also potentiated the contralateral rotation seen after 1-dopa (5-20 mg/kg). In contrast, d-amphetamine, which by itself caused ipsilateral rotation, failed to potentiate the rotation after 1-dopa. Possible mechanisms for these observations will be discussed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6794038     DOI: 10.1016/0091-3057(81)90342-7

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  8 in total

1.  Biphasic effects of selegiline on striatal dopamine: lack of effect on methamphetamine-induced dopamine depletion.

Authors:  K Grasing; R Azevedo; S Karuppan; S Ghosh
Journal:  Neurochem Res       Date:  2001-01       Impact factor: 3.996

2.  Potentiation of central effects of L-dopa by an inhibitor of catechol-O-methyltransferase.

Authors:  J Nuutila; S Kaakkola; P T Männistö
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

3.  Selective inhibition of monoamine oxidase type B by MDL 72145 increases the central effects of L-dopa without modifying its cardiovascular effects.

Authors:  J R Fozard; M G Palfreyman; M Robin; M Zreika
Journal:  Br J Pharmacol       Date:  1986-01       Impact factor: 8.739

4.  Effect of monoamine oxidase A and B and of catechol-O-methyltransferase inhibition on L-DOPA-induced circling behavior.

Authors:  M J Heeringa; F d'Agostini; P DeBoer; M DaPrada; G Damsma
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

5.  Synergistic interactions between COMT-/MAO-inhibitors and L-Dopa in MPTP-treated mice.

Authors:  A Fredriksson; T Archer
Journal:  J Neural Transm Gen Sect       Date:  1995

6.  The functional consequences of inhibition of monoamine oxidase type B: comparison of the pharmacological properties of L-deprenyl and MDL 72145.

Authors:  J R Fozard; M Zreika; M Robin; M G Palfreyman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-11       Impact factor: 3.000

7.  Locomotor effects of imidazoline I2-site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway.

Authors:  Nicholas Macinnes; Susan Duty
Journal:  Br J Pharmacol       Date:  2004-11-15       Impact factor: 8.739

Review 8.  Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.

Authors:  Susan Duty; Peter Jenner
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.